Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy.

By O. Koç, Stanton L. Gerson, B. Cooper, Stephanie M. Dyhouse, S. Haynesworth, A. Caplan, H. Lazarus. Journal of Clinical Oncology, 2000

1,169 citations recorded by the source corpus.

Subfields: Genetics, Hematology, Oncology

View Paper: https://www.semanticscholar.org/paper/3cf9002cd1b5f9c291718d1a4c1ab9b9f0ad8e82

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. A. Caplan
2. N. Singer
3. O. Ringdén
4. Frank Barry
5. W. Fibbe

In Hematology

1. A. Caplan
2. O. Ringdén

In Oncology

1. A. Caplan
2. Hanns-Ulrich Marschall
3. O. Ringdén

Citations in the corpus

• Immunomodulatory effect of human adipose tissue‐derived adult stem cells: comparison with bone marrow mesenchymal stem cells (2005, background): “Co-transplantation of human BMMSCs and haematopoietic stem cells seems to improve haematopoiesis after myeloablative therapy in breast cancer patients through reconstitution of the BM stroma (Koc et al, 2000).”
• HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. (2003, background): “Cotransplantation of autologous MSC and hematopoietic stem cells (HSC) may enhance HSC engraftment [8].”
• Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease (2006, result): “No side-effects were noted after the infusion of HLA-identical or mismatched MSC, which in the allogeneic setting confirms previous studies using autologous or HLA-identical MSC posttransplant in patients with metabolic disorders (37, 38, 40).”
• Autologous mesenchymal stem cell transplantation in stroke patients (2005, background): “5 days; range, 23–37 days), as reported previously.(10) Based on mean body mass, 1 10(8) cells/patient is the human dose equivalent to the dose that was effective in a rat model of stroke (1 10(5) ̃ 3 10(6) cells/rat).”
• Mesenchymal stem cells avoid allogeneic rejection (2005, methodology): “In a previous study by the same group, autologous cultureexpanded MSC were infused to breast cancer patients to investigate whether MSC would enhance the engraftment of peripheral blood stem cells after myeloablative therapy [17].”